U.S. Buys 600,000 More Doses of GSK-Vir’s Antibody COVID-19 Treatment | U.S. News®


(Reuters) – British drugmaker GSK and U.S. partner Vir Biotechnology said on Tuesday the United States had agreed to buy 600,000 more doses of their antibody-based COVID-19 treatment, sotrovimab, for an undisclosed amount.

With the latest deal, about 1.7 million doses of the treatment, branded Xevudy, have been secured by countries so far globally.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)

Copyright 2022 Thomson Reuters.